News Agency
The Times

Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma

  • Written by PR Newswire
Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma

140 patients have been recruited at sites in Spain, Italy, France and United Kingdom.The open readout of the trial is expected by late 2024.Laminar aims to submit regulatory filings or conditional marketing authorization by early 2025.

PALMA DE MALLORCA, Spain, June 12, 2024 /PRNewswire/ -- Laminar Pharmaceuticals S.A., a clinical-stage...

Read more: Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3...

How Australian Businesses Can Prepare Their Websites for AI-Powered Search Results

Search is changing rapidly. While traditional search engines remain a major source of website traffic, customers are increasingly using AI-powered platforms to discover information, compare businesses and make purchasing decisions. For Australian businesses, this shift creates a new challenge: ensuring... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion